Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.73 |
| ▸ | HTR2A | P28223 | 8/20 | 0.73 |
| ▸ | HTR2B | P41595 | 9/20 | 0.71 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 8/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366067 | 1.00 | HTR2C (0.73) | HTR2CHTR2AHTR2BDRD2HTR6 | |
| SCHEMBL11469428 | 0.90 | HTR2C (0.60) | HTR2CHTR2AHTR2BDRD2HTR6 | |
| SCHEMBL6713653 | 0.85 | HTR2C (1.00) | HTR2CHTR2AHTR2BDRD2 | |
| SCHEMBL692120 | 0.85 | HTR2C (0.69) | HTR2CHTR2AHTR2BDRD2 | |
| SCHEMBL30396809 | 0.83 | HTR2C (1.00) | HTR2CHTR2AHTR2B | |
| SCHEMBL3265754 | 0.83 | HTR2C (1.00) | HTR2CHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL7233743 | 0.82 | HTR2C (0.97) | HTR2CHTR2AHTR2B | |
| SCHEMBL691824 | 0.81 | HTR2C (0.83) | HTR2CHTR2AHTR2B | |
| SCHEMBL692196 | 0.80 | HTR2C (0.62) | HTR2CHTR2AHTR2BDRD2 | |
| SCHEMBL24187328 | 0.78 | HTR2C (0.57) | HTR2CHTR2AHTR2BDRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022007866-A1 | FUSED TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2022-01-13 | — | — | WO | disclosed |
| EP-2989105-B1 | PYRAZINO[1,2-A]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS SA (ES) | 2020-03-11 | — | — | EP | disclosed |
| EP-2989104-B1 | PYRAZINO[1,2-A]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS SA (ES) | 2019-08-21 | — | — | EP | disclosed |
| US-9879015-B2 | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-01-30 | — | — | US | disclosed |
| US-9879015-B2 | Pyrazino[1,2-a]indole compounds, their preparation and use in medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2018-01-30 | — | — | US | disclosed |
| US-20160060268-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2016-03-03 | — | — | US | disclosed |
| WO-2014173903-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2014-10-30 | — | — | WO | disclosed |
| US-7253281-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253281-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | BENTLEY JONATHAN M | 2007-05-10 | — | — | US | disclosed |
| EP-1147110-B1 | PYRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RES LTD (GB) | 2003-05-07 | — | — | EP | disclosed |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) | 2002-03-21 | — | — | US | disclosed |
| EP-1147110-A1 | PYRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RESEARCH LIMITED (GB) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044753-A1 | PIRAZINO(AZA)INDOLE DERIVATIVES | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| US-5622950-A | Pyrrolo-pyridine derivatives | MERCK, SHARP & DOHME LTD. (GB) | 1997-04-22 | — | — | US | disclosed |
| US-5576319-A | Pyrrolo-pyridine derivatives | MERCK, SHARP & DOHME LTD. (GB) | 1996-11-19 | — | — | US | disclosed |
| US-5432177-A | Pyrrolo-pyridine derivatives | MERCK SHARPE & DOHME LTD. (GB) | 1995-07-11 | — | — | US | disclosed |
| EP-0623618-A2 | Pyrrolo-pyridine derivatives | MERCK SHARP & DOHME LTD. (GB) | 1994-11-09 | — | — | EP | disclosed |
| WO-1994020497-A1 | PYRROLO-PYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1994-09-15 | — | — | WO | disclosed |
| US-4070357-A | Process for the preparation of indoline derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DT) | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | GPR119, INSR, GIPR | HTR2C 77/4885HTR2A 68/4885HTR2B 93/4885 |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | GPR119, HTR1D, HTR1A | HTR2C 34/4885HTR2A 16/4885HTR2B 61/4885 |
| US-20160060268-A1 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS | IDO1, TPH1, IDO2 | HTR2C 24/4885HTR2A 25/4885HTR2B 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.